boonk
2021-10-07
Bye bye
Tilray gained over 4% in premarket trading
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
44
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":823143647,"tweetId":"823143647","gmtCreate":1633606187956,"gmtModify":1633616397922,"author":{"id":3580955744929134,"idStr":"3580955744929134","authorId":3580955744929134,"authorIdStr":"3580955744929134","name":"boonk","avatar":"https://static.tigerbbs.com/6e58310c6a80ddfbcb69e0989cda7858","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":81,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Bye bye</p></body></html>","htmlText":"<html><head></head><body><p>Bye bye</p></body></html>","text":"Bye bye","highlighted":2,"essential":1,"paper":1,"likeSize":2,"commentSize":44,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/823143647","repostId":1151380522,"repostType":4,"repost":{"id":"1151380522","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1633594837,"share":"https://www.laohu8.com/m/news/1151380522?lang=&edition=full","pubTime":"2021-10-07 16:20","market":"us","language":"en","title":"Tilray gained over 4% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1151380522","media":"Tiger Newspress","summary":"(Oct 7) Tilray Inc. gained over 4% in premarket trading, After a strong Q421 performance, Tilray is ","content":"<p>(Oct 7) <a href=\"https://laohu8.com/S/TLRY\">Tilray Inc.</a> gained over 4% in premarket trading, After a strong Q421 performance, Tilray is scheduled to announce the FQ1 earnings results of FY22 before market open.</p>\n<p><img src=\"https://static.tigerbbs.com/6d5739bed1bc4a8f88cac32a7a06bd61\" tg-width=\"1066\" tg-height=\"576\" referrerpolicy=\"no-referrer\"></p>\n<p>The consensusEPS Estimate is -$0.07vs -$0.02 in FQ1 of FY21 and the consensus Revenue Estimate is $174.93M (+20.1% Y/Y).</p>\n<p>Tilray is also focused on lowering its cost in several ways, and the results of its cost-saving efforts are already beginning to show up. In itsQ421 earnings call, the company indicated that its average cost per gram came in at $0.72, owing to improve yield, potency and cost control efforts that began in January. At the time, the management had also warned of a negative impact of $2.5M-$4M in Q122 net revenues, as the recent floods in Germany directly affected CC Pharma, which Aphria acquired in 2019.</p>\n<p>Over the past three months, Tilrayacquireda majority of outstanding convertible notes of MedMen Enterprises as the company eyes the U.S. market in the event of federal legalization. Commenting on the transaction, <a href=\"https://laohu8.com/S/BAC\">Bank of America</a> said that it sees the investment as apositive sign for Tilray, giving the company a foothold in the U.S. market with potential distribution opportunities with MedMen in Canada and Europe.</p>\n<p>More recently, Tilray stockholders approved anincrease in the number of authorized shares of its common stock. With the additional authorized shares, Tilray is positioned to progress towards its goal of delivering $4B in revenue by FY24 end. The company is also targeting an increase in its retail market share from 16% to 30% by FY24 end.</p>\n<p>Over the last 2 years, TLRYhas beaten EPS estimates38% of the time and has beaten revenue estimates 38% of the time.</p>\n<p>Over the last 3 months, EPS estimates have seen 3upward revisionsand 1 downward. Revenue estimates have seen 1 upward revision and 7 downward.</p>\n<p>The medical cannabis producer reported net revenue of $142.2M in Q421, up 25% Y/Ybut missing estimates. The revenue growth was attributed to a 36% rise in net cannabis revenue. The company ended the year with net revenue of $513.1M (+27% Y/Y), a significantly increased adj. EBITDA and a strong balance sheet and liquidity, includingcash and cash equivalents of $488.5M.</p>\n<p>Tilray management is currently executing on a plan to drive accelerate growth and sustained profitability in global cannabis market. In the previous quarter, Tilray completed its business combination with Aphria. This strategic reverse acquisition is already showing synergistic results for TLRY, generating $35M in realized savings and is likely to generate upwards of $80M in synergies over the next 18 months.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tilray gained over 4% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTilray gained over 4% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-07 16:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Oct 7) <a href=\"https://laohu8.com/S/TLRY\">Tilray Inc.</a> gained over 4% in premarket trading, After a strong Q421 performance, Tilray is scheduled to announce the FQ1 earnings results of FY22 before market open.</p>\n<p><img src=\"https://static.tigerbbs.com/6d5739bed1bc4a8f88cac32a7a06bd61\" tg-width=\"1066\" tg-height=\"576\" referrerpolicy=\"no-referrer\"></p>\n<p>The consensusEPS Estimate is -$0.07vs -$0.02 in FQ1 of FY21 and the consensus Revenue Estimate is $174.93M (+20.1% Y/Y).</p>\n<p>Tilray is also focused on lowering its cost in several ways, and the results of its cost-saving efforts are already beginning to show up. In itsQ421 earnings call, the company indicated that its average cost per gram came in at $0.72, owing to improve yield, potency and cost control efforts that began in January. At the time, the management had also warned of a negative impact of $2.5M-$4M in Q122 net revenues, as the recent floods in Germany directly affected CC Pharma, which Aphria acquired in 2019.</p>\n<p>Over the past three months, Tilrayacquireda majority of outstanding convertible notes of MedMen Enterprises as the company eyes the U.S. market in the event of federal legalization. Commenting on the transaction, <a href=\"https://laohu8.com/S/BAC\">Bank of America</a> said that it sees the investment as apositive sign for Tilray, giving the company a foothold in the U.S. market with potential distribution opportunities with MedMen in Canada and Europe.</p>\n<p>More recently, Tilray stockholders approved anincrease in the number of authorized shares of its common stock. With the additional authorized shares, Tilray is positioned to progress towards its goal of delivering $4B in revenue by FY24 end. The company is also targeting an increase in its retail market share from 16% to 30% by FY24 end.</p>\n<p>Over the last 2 years, TLRYhas beaten EPS estimates38% of the time and has beaten revenue estimates 38% of the time.</p>\n<p>Over the last 3 months, EPS estimates have seen 3upward revisionsand 1 downward. Revenue estimates have seen 1 upward revision and 7 downward.</p>\n<p>The medical cannabis producer reported net revenue of $142.2M in Q421, up 25% Y/Ybut missing estimates. The revenue growth was attributed to a 36% rise in net cannabis revenue. The company ended the year with net revenue of $513.1M (+27% Y/Y), a significantly increased adj. EBITDA and a strong balance sheet and liquidity, includingcash and cash equivalents of $488.5M.</p>\n<p>Tilray management is currently executing on a plan to drive accelerate growth and sustained profitability in global cannabis market. In the previous quarter, Tilray completed its business combination with Aphria. This strategic reverse acquisition is already showing synergistic results for TLRY, generating $35M in realized savings and is likely to generate upwards of $80M in synergies over the next 18 months.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151380522","content_text":"(Oct 7) Tilray Inc. gained over 4% in premarket trading, After a strong Q421 performance, Tilray is scheduled to announce the FQ1 earnings results of FY22 before market open.\n\nThe consensusEPS Estimate is -$0.07vs -$0.02 in FQ1 of FY21 and the consensus Revenue Estimate is $174.93M (+20.1% Y/Y).\nTilray is also focused on lowering its cost in several ways, and the results of its cost-saving efforts are already beginning to show up. In itsQ421 earnings call, the company indicated that its average cost per gram came in at $0.72, owing to improve yield, potency and cost control efforts that began in January. At the time, the management had also warned of a negative impact of $2.5M-$4M in Q122 net revenues, as the recent floods in Germany directly affected CC Pharma, which Aphria acquired in 2019.\nOver the past three months, Tilrayacquireda majority of outstanding convertible notes of MedMen Enterprises as the company eyes the U.S. market in the event of federal legalization. Commenting on the transaction, Bank of America said that it sees the investment as apositive sign for Tilray, giving the company a foothold in the U.S. market with potential distribution opportunities with MedMen in Canada and Europe.\nMore recently, Tilray stockholders approved anincrease in the number of authorized shares of its common stock. With the additional authorized shares, Tilray is positioned to progress towards its goal of delivering $4B in revenue by FY24 end. The company is also targeting an increase in its retail market share from 16% to 30% by FY24 end.\nOver the last 2 years, TLRYhas beaten EPS estimates38% of the time and has beaten revenue estimates 38% of the time.\nOver the last 3 months, EPS estimates have seen 3upward revisionsand 1 downward. Revenue estimates have seen 1 upward revision and 7 downward.\nThe medical cannabis producer reported net revenue of $142.2M in Q421, up 25% Y/Ybut missing estimates. The revenue growth was attributed to a 36% rise in net cannabis revenue. The company ended the year with net revenue of $513.1M (+27% Y/Y), a significantly increased adj. EBITDA and a strong balance sheet and liquidity, includingcash and cash equivalents of $488.5M.\nTilray management is currently executing on a plan to drive accelerate growth and sustained profitability in global cannabis market. In the previous quarter, Tilray completed its business combination with Aphria. This strategic reverse acquisition is already showing synergistic results for TLRY, generating $35M in realized savings and is likely to generate upwards of $80M in synergies over the next 18 months.","news_type":1},"isVote":1,"tweetType":1,"viewCount":297,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":6,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/823143647"}
精彩评论